Kineta Nabs $600K NIH Grant

Luke Timmerman4/5/10

Kineta, the Seattle-based developer of treatments for autoimmune diseases, said it has received a two-year, $600,000 grant from the National Institutes of Health to do work that could enable clinical trials of a new drug for Type 1 diabetes, multiple sclerosis and other autoimmune diseases. Kineta said it plans to start clinical trials on the drug in the second half of 2010.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @